Biopharma and Medtech Half-Year Review 2021

Despite the continuing pandemic, the biopharma sector saw a return to relative stability during the first half of 2021. Remote operations are proving effective, deals are being made, and clinical research has resumed in many areas.

Compared to the same period in 2020, the medtech industry has witnessed a reversal of fortunes. Those producing Covid-19 tests and treatment technologies have lost headway, while demand for devices used in non-urgent procedures, in the orthopaedic and cardiovascular fields for instance, is surging.

Report Highlights:

  • Moderna is the standout example in biotech, touching $196bn in early August and overtaking established players AstraZeneca and Bristol Myers Squibb.
  • Biopharma M&A had a quiet start to 2021, with only one takeover surpassing $500m – Morphosys’s $1.7bn takeover of Constellation.
  • After a stormy 18 months, the overall climate for medical device, diagnostics and digital health companies is improving, remaining steadfastly average in the first six months of 2021.
  • That said, biopharma remains a highly active in-licensor of innovation, as revealed by insights from BioSciDB, acquired by Evaluate earlier this year.

For an in-depth view on these and other market-shaping developments, read the Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2021.


Covid-19 treatment and
Alzheimer’s players are among
the biggest stock gainers.
Eli Lilly and Roche account for
more than half of the big
pharma market cap expansion
over the period.
Biopharma M&A had
a quiet start to 2021.
$15bn of biopharma
venture investment raised
in the first half of the year.
More than $10bn-worth
of medtech deals were
announced in January alone.
Will medtech face uncertainty
around the FDA’s approach
after the appointment of a
permanent commissioner?